Development of the RapidMist™ drug delivery system for the treatment of diabetes, cardiovascular diseases and breakthrough cancer pain

Drugs of the Future

Volumn 30, Issue 3, 2005, Pages 271-276

  Modi, Pankaj ^a  

^a NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; FENTANYL; FENTANYL CITRATE; GLUCOSE; HYDROMORPHONE; INSULIN; INSULIN LISPRO; LOW MOLECULAR WEIGHT HEPARIN; MORPHINE; OPIATE; RECOMBINANT HUMAN INSULIN;

BOLUS INJECTION; CANCER PAIN; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DEVICE; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; GLUCOSE BLOOD LEVEL; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; LUNG EMBOLISM; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; REVIEW; SIDE EFFECT; TECHNIQUE;

EID: 18844450206     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2005.030.03.891450     Document Type: Review

References (14)

1. Verma, R.K., Garg, S. Current status of drug delivery technologies and future directions. Pharm Tech On-line 2001, 25(2): 1-14.
2. Henry, C.M. Special delivery: Alternative methods for delivering drugs improve performance, convenience and patient compliance. Chem Eng News 2000, 78(38): 49-65.
3. Kermani, F., Findlay, G. Novel drug delivery technologies: A perspective from the pharmaceutical industry. Am Pharm Outsourcing 2001, 22-9.
4. Leone-Bay, A., Paton, D.R., Weidner, J.J. The development of delivery agents that facilitate the oral absorption of macromolecular drugs. Med Res Rev 2000, 20: 169-86.
5. Cefalu, W.T. Concept, strategies, and feasibility of noninvasive insulin delivery. Diabetes Care 2004, 27(1): 239-46.
6. Chetty, D.J., Chein, Y.W. Novel methods of insulin delivery: An update. Crit Rev Ther Drug Carrier Syst 1998, 15(6): 629-70.
7. Clement, S., Still, G., Kosutic, G. et al. Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: The glucose stabilization effects of HIM2. Diabetes Tech Ther 2002, 4: 459-66.
8. Still, J.G.L. Development of oral insulin: Progress and current status. Diabetes Metab Res Rev 2002, 18(Suppl.): S29-37.
9. Guevara-Aguirre, J., Guevara, M., Saavedra, J., Modi, P. Beneficial effects of addition of oral spray insulin (Oralin) on insulin secretion and metabolic control in subjects with type 2 diabetes mellitus suboptimally controlled on oral hypoglycemic agents. Diabetes Tech Ther 2004, 6(1): 1-8.
10. Guevara-Aguirre, J., Guevara, M., Saavedra, J., Mihic, M., Modi, P. Oral spray insulin in treatment of type 2 diabetes: A comparison of efficacy of the oral spray insulin (Oralin) with subcutaneous (SC) insulin injection, a proof of concept study. Diabetes Metab Res Rev 2004, 20(6): 472-8.
11. Levin, P., Yutzy, P., Chez, N., Modi, P. Improved post-prandial glucose control with Oralin at breakfast, lunch and dinner-time. Diabetes 2001, 50(Suppl. 2): A124.
12. Raz, I., Kidron, M., Wohlgernter, J., Modi, P. Time action profile of Oralin in comparison with s.c. injected insulin in type-1 diabetic patients under euglycemic clamp technique. Diabetes 2003, 52(Suppl. 1): A107.
13. Guevara-Aguirre, J., Guevara, M., Saavedra, J., Moncayo, P., Benitez, E., Modi, P. Dose ranging study of Oralin in healthy subjects. Diabetes 2003, 52(Suppl. 1): A104.
14. Collins, S.L., Faura, C.C., Moore, R.A., McQuay, H.J. Peak plasma concentrations after oral fentanyl - A systematic review. J Pain Symptom Manage 1998, 16: 388-402.